Form 4: Thermo Fisher COO Exercises Options, Sells Shares

Thermo Fisher Scientific's Executive Vice President and COO, Michel Lagarde, exercised stock options and subsequently sold a portion of the acquired common stock for over $36 million.

Summary

• Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific Inc. (TMO), engaged in multiple transactions involving the company's common stock.
• On December 2, 2025, Lagarde exercised options to acquire 36,000 shares of common stock at an exercise price of $105.17 per share.
• On the same day, 30,000 shares of common stock were sold at a weighted average price of $581.92 per share, with individual sales ranging from $581.90 to $582.33.
• On December 3, 2025, Lagarde exercised options to acquire an additional 68,000 shares of common stock at $105.17 per share.
• Also on December 3, 2025, a total of 32,000 shares were sold in two separate transactions: 29,479 shares at a weighted average price of $583.33 (ranging from $583.03 to $583.96) and 2,521 shares at a weighted average price of $584.11 (ranging from $584.00 to $584.533).
• Following these transactions, Lagarde's direct beneficial ownership of common stock is 65,479.909 shares, and 18,637 derivative securities (stock options).
• The options exercised had vested in two equal installments on August 29, 2017, and August 29, 2020, with an expiration date of July 20, 2026.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (option exercise and share sales) by a senior executive. While insider selling can sometimes be viewed negatively, these appear to be part of a planned compensation realization strategy and do not indicate any specific positive or negative operational news for the company.

Positives

• Michel Lagarde realized significant proceeds of over $36 million from the sale of shares, demonstrating the value of executive compensation plans tied to company performance.

Negatives

• Insider selling, even if routine, can sometimes be perceived negatively by the market, though these transactions appear to be part of a planned exercise-and-sell strategy.

Future Outlook

NA

Industry Context

This filing details routine insider transactions, specifically the exercise of stock options and subsequent sale of shares by a senior executive. Such transactions are common in the life sciences and diagnostics industry, as executives monetize vested equity compensation. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: The sale of shares by a senior executive could be perceived as a minor signal, but given the routine nature of option exercises and sales for compensation, the impact is likely minimal. The executive retains a significant number of shares and options, indicating continued alignment with shareholder interests.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions where an executive exercised vested stock options and sold a portion of the acquired shares. Such transactions are common for executive compensation and personal financial planning. There is no new operational or strategic information about Thermo Fisher Scientific Inc. that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on the company's fundamentals rather than these routine insider sales.

Keywords

Thermo Fisher Scientific, TMO, Michel Lagarde, Insider Trading, Stock Options, Executive Compensation, SEC Form 4, Share Sale, Option Exercise